Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock Has Consensus Target Price of $6.40 According to Analysts

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $6.40.

Several research firms recently issued reports on MIST. HC Wainwright reiterated a “buy” rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd. Zacks Research upgraded Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, July 14th. Finally, Cantor Fitzgerald assumed coverage on shares of Milestone Pharmaceuticals in a report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 target price on the stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MIST. Eaton Financial Holdings Company LLC purchased a new stake in shares of Milestone Pharmaceuticals in the fourth quarter worth about $26,000. HighTower Advisors LLC grew its holdings in shares of Milestone Pharmaceuticals by 100.0% in the second quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock valued at $27,000 after purchasing an additional 10,000 shares in the last quarter. Welch & Forbes LLC bought a new stake in Milestone Pharmaceuticals in the first quarter worth $30,000. Bay Rivers Group increased its position in Milestone Pharmaceuticals by 55.9% in the second quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock worth $62,000 after purchasing an additional 16,722 shares during the last quarter. Finally, TRU Independence Asset Management 2 LLC purchased a new stake in Milestone Pharmaceuticals during the fourth quarter valued at $202,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Stock Down 0.8%

Shares of MIST stock opened at $0.79 on Monday. The company has a market capitalization of $98.16 million, a price-to-earnings ratio of -1.14 and a beta of 0.98. Milestone Pharmaceuticals has a one year low of $0.75 and a one year high of $3.06. The company’s fifty day moving average price is $1.09 and its 200-day moving average price is $1.37. The company has a debt-to-equity ratio of 3.25, a current ratio of 8.13 and a quick ratio of 7.92.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.82 million. Sell-side analysts expect that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing therapies for cardiovascular conditions. The company’s lead product is etripamil, a short-acting, non-dihydropyridine calcium channel blocker formulated as a self-administered nasal spray.

Etripamil has been developed primarily for the rapid treatment of paroxysmal supraventricular tachycardia (PSVT), a form of abnormally fast heart rhythm that can begin and end suddenly. Milestone has also evaluated the therapy in other cardiovascular applications, including the potential treatment of angina and related conditions.

Founded in 2012, Milestone is headquartered in Montreal, Quebec, and has conducted clinical development activities in North America.